Determination of association between the polymorphism in exon 3 of dopamine receptor gene type 4 with attention deficit-hyperactivity disorder

Introduction: Evidences suggest that attention deficit-hyperactivity disorder (ADHD) is a hereditary disorder and at least 20 potential genes associated with ADHD have been identified. Dopamine receptor gene type 4 (DRD4) has been more considered due to a stronger relationship with ADHD. However, no study has yet been conducted on the Iranian population to assess the association. Objective: In this study, the association between polymorphism of DRD4 gene with ADHD has been studied among capital of Iran population. Materials and methods: This study is a case-control study conducted on children aged 6�12 years with ADHD referred to child and adolescent psychiatric clinic Imam Hussein (AS) and normal subjects in 2011. Diagnosis was done based on the DSM-IV-TR criteria and interviewing by two child and adolescent psychiatrists. If parental were consent, then saliva samples of subjects were prepared and DRD4 gene and related allele were evaluated using PCR method. The K-SADS questionnaire was also used to assess comorbid disorders. Results: In this study, 114 patients in ADHD group and 109 patients in the control group were studied. The most frequency was obtained for allele 4 allele that has been observed in about 90 of both case and control groups. However, frequency of allele 6 in the case group was 8.8 where the frequency was 5 in the control group (p = 0.02). The presence of repeat of allele 6 increased chance of suffering from ADHD to 1.809 (95 equal to 3.871�0.845). Conclusion: For the first time this study showed that in Iranian population repeat of DRD4 gene allele 6 unlike the other geographic areas is relatively common and it will increase the chances of suffering from ADHD. However, additional studies are required. © 201

Microstructural evolution in solution heat treatment of gas- atomised Al alloy (7075) powder for cold spray

Cold gas dynamic spray is being explored as a repair technique for high-value metallic components, given its potential to produce pore and oxide-free deposits of between several micrometers and several millimeters thick with good levels of adhesion and mechanical strength. However, feedstock powders for cold spray experience rapid solidification if manufactured by gas atomization and hence can exhibit non-equilibrium microstructures and localized segregation of alloying elements. Here, we used sealed quartz tube solution heat treatment of a precipitation hardenable 7075 aluminum alloy feedstock to yield a consistent and homogeneous powder phase composition and microstructure prior to cold spraying, aiming for a more controllable heat treatment response of the cold spray deposits. It was shown that the dendritic microstructure and solute segregation in the gas-atomized powders were altered, such that the heat-treated powder exhibits a homogeneous distribution of solute atoms. Micro-indentation testing revealed that the heat-treated powder exhibited a mean hardness decrease of nearly 25% compared to the as received powder. Deformation of the powder particles was enhanced by heat treatment, resulting in an improved coating with higher thickness (* 300 lm compared to * 40 um for untreated feedstock). Improved particle–substrate bonding was evidenced by formation of jets at the particle boundaries

Advances in understanding and treating ADHD

Attention deficit hyperactivity disorder (ADHD) is a neurocognitive behavioral developmental disorder most commonly seen in childhood and adolescence, which often extends to the adult years. Relative to a decade ago, there has been extensive research into understanding the factors underlying ADHD, leading to far more treatment options available for both adolescents and adults with this disorder. Novel stimulant formulations have made it possible to tailor treatment to the duration of efficacy required by patients, and to help mitigate the potential for abuse, misuse and diversion. Several new non-stimulant options have also emerged in the past few years. Among these, cognitive behavioral interventions have proven popular in the treatment of adult ADHD, especially within the adult population who cannot or will not use medications, along with the many medication-treated patients who continue to show residual disability

Effect of therapeutic intervention on general health of child abused mothers

Background and Objective: Child abuse is a common phenomenon with variety of reasons; the most important one is mother psychiatric disorders. Concurrent interventions in the family can recover the mother and reduce child abuse. This study was done to evaluate the effect of therapeutic intervention on general health of child abused mothers. Methods: This clinical trial study was conducted on 57 children and their child abused mothers whom referred to child psychiatry and pediatric department of Imam Hossien hospital, Tehran, Iran during November 2009- April 2010. Children and their families were visited by a psychiatrist and depend on the child and the family after either pharmaceutical or psychological interventions was taken. Parent management training was done for all mothers in 8 weekly sessions. General health questionnaire were filled by mothers before intervention in the third and sixth months following the intervention. Results: Total score of general health, depression and anxiety of child abused mothers were 31.3±1.90, 5.26±0.66, 8.10±0.46, respectively. It was significantly increased after six months intervention in comparison with pre-intervention (37.3±2.34, 7.48±0.72, 10.44±0.58, respectively). Conclusion: Appropriate therapeutic intervention and parent management training for mothers can improve general health of child abused mothers

Six week open-label reboxetine treatment in children and adolescents with attention deficit hyperactivity disorder

Background: Attention Deficit Hyperactivity Disorder (ADHD) is a common psychiatric disorder among children and adolescents. This disorder causes difficulties in academic, behavioral, emotional, social and family performance. Stimulants show robust efficacy and a good safety profile in children with this disorder, but a significant percent of ADHD children do not respond adequately or cannot tolerate the associated adverse effects with stimulants. Such difficulties highlight the need for alternative safe and effective medications in the treatment of this disorder. This open-label study assessed the effectiveness of reboxetine, a selective norepinephrine reuptake inhibitor, in children and adolescents with attention deficit hyperactivity disorder (ADHD)."nMethods: Fifteen child and adolescent outpatients, aged 7 to 16 (Mean± SD=9.72±2.71) years, diagnosed with ADHD were enrolled in a six open-label study with reboxetine 4-6 mg/d. The principal measure of the outcome was the teacher and parent Attention Deficit Hyperactive Disorder Rating Scale (ADHD Rating Scale). Patients were assessed by a child psychiatrist at baseline, 2, 4 and 6 weeks of the medication started. Side effects questionnaire was used to detect side effects of reboxetine. Repeated measures Analysis of variance (ANOVA) was done for comparison of Teacher and Parent ADHD Rating Scale scores during the intervention."nResults: Twelve of 15 (80%) participants completed the treatment protocol. A significant decrease in ADHD symptoms on teacher (p=0.04) and parent (p=0.003) ADHD rating scale was noted. Adverse effects were mild to moderate in severity. The most common adverse effects were drowsiness/sedation and appetite decrease."nConclusion: The results of the current study suggest the effectiveness of reboxetine in the treatment of ADHD in children and adolescents. Double-blind, placebo-controlled studies and larger sample size with long duration of intervention are indicated to rigorously test the efficacy of reboxetine in ADHD. It is important that future studies complete our knowledge about safety and side effects of reboxetine

Validity of a Farsi translation of the composite International Diagnostic Interview (CIDI) to diagnose schizophrenia and bipolar disorder

Background: The Composite International Diagnostic Interview (CIDI) is a comprehensive, standardized diagnostic interview for the assessment of psychiatric disorders. There have been few studies on the validity of the CIDI. The objective of present study was to assess the validity of a Farsi translation of the complete CIDI and its psychosis/mania module in five referral clinical psychiatric settings. Methods: Two hundred and three as well as 104 consecutive admissions were interviewed using the complete and the psychosis/mania module, respectively. Within two days of the CIDI interview, two last year residents of psychiatry or psychiatrist who were blind to the CIDI diagnosis completed the Clinical diagnostic checklists (based on DSM-IV and ICD-10 criteria) simultaneously and reached the consensus diagnosis. Data analysis was performed using SPSS 11 to determine the validity of CIDI. Results: The sensitivity and specificity for the diagnosis of schizophrenia was 0.12 and 0.96 using DSM-IV criteria. According to ICD-10 criteria, the results were the same with 0.19% sensitivity and 0.96% specificity. The sensitivity for the diagnosis of bipolar I disorder was low (0.21 using DSM-IV criteria and 0.17% using ICD-10) and specificity, high (0.90 compared to DSM-IV and 0.89 compared to ICD-10 criteria). The results were rather similar for the psychosis/mania module of CIDI. Conclusion: This study suggests that the Farsi translation of both the complete CIDI and the psychosis/mania module of CIDI have good specificity, but poor sensitivity for the diagnosis of schizophrenia and of bipolar I disorder